SCHEMBL5268433

SCHEMBL5268433

COc1ccc2c(c1)Cc1cc3cc(OC)ccc3c(-c3cccc(OCc4ccccc4)c3)c1-2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 3/20 0.49
ALOX5 P09917 7/20 0.48
P2RY14 Q15391 1/20 0.43
DYRK1B Q9Y463 1/20 0.42
HRH3 Q9Y5N1 2/20 0.41
BCHE P06276 1/20 0.40
ERN1 O75460 1/20 0.40
MAOA P21397 1/20 0.40
FFAR1 O14842 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
ADRA2B P18089 1/20 0.40
ADRA2C P18825 1/20 0.40
DRD4 P21917 1/20 0.40
SLC6A2 P23975 1/20 0.40
HTR2C P28335 1/20 0.40
SLC6A4 P31645 1/20 0.40
OPRK1 P41145 1/20 0.40
HTR2B P41595 1/20 0.40
HTR5A P47898 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5264527 0.91 ALOX5 (0.47) MAOBALOX5P2RY14HRH3BCHE
SCHEMBL6668074 0.80 MAOB (0.54) MAOBALOX5P2RY14DYRK1BBCHE
SCHEMBL225278 0.74 MAOB (0.61) MAOBALOX5BCHEFFAR1
SCHEMBL9405631 0.70 MAOB (0.71) MAOBBCHEERN1FFAR1
SCHEMBL791569 0.69 MAOB (1.00) MAOBBCHEHTR1A
SCHEMBL25876813 0.69 MAOB (0.44) MAOBHTR1A
SCHEMBL7096339 0.69 L3MBTL1 (0.57) MAOBDYRK1BBCHEERN1
SCHEMBL6087375 0.69 NPSR1 (0.58) MAOBALOX5P2RY14
SCHEMBL6086702 0.69 MGAM (0.56) MAOBALOX5P2RY14SLC6A2SLC6A3
SCHEMBL29561154 0.68 CYP11B1 (0.48) MAOBALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272471-B1 NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS ORGANON NV (NL) 2007-10-03 EP claimed
EP-1272471-B1 NON-STEROIDAL, TETRACYCLIC COMPOUNDS FOR ESTROGEN-RELATED TREATMENTS ORGANON NV (NL) 2007-10-03 EP disclosed
US-6686371-B2 HAVING AN 11H-BENZO(B)FLUORENE, AN 11H-INDENO-(1,2-B) QUINOLINE, A BENZ(A)ANTHRACENE OR ANALOGOUS SKELETON AND AN AFFINITY FOR THE ESTROGEN RECEPTOR; CONTRACEPTIVES; MENOPAUSAL COMPLAINTS, OSTEOPOROSIS; ANTITUMOR AGENTS AKZO NOBEL N.V. (NL) 2004-02-03 US disclosed
US-20030144313-A1 Non-steroidal, tetracylic compounds for estrogen-related treatments N.V. ORGANON (NL) 2003-07-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144313-A1 Non-steroidal, tetracylic compounds for estrogen-related treatments ESRRA, ESRRB, ESRRG MAOB 3356/4885ALOX5 1158/4885P2RY14 4166/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.